Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OT-A201 + IMiDs
- Development stage
- Unknown
- Lead developer
- Onward Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
OT-A201 + IMiDs is a combination therapy being developed by Onward Therapeutics for the treatment of advanced hematological malignancies. The regimen consists of OT-A201, a first-in-class humanized bispecific antibody targeting two immune checkpoints, and an immunomodulatory imide drug (IMiD) such as lenalidomide or pomalidomide. OT-A201, licensed from Biomunex Pharmaceuticals, utilizes the proprietary BiXAb technology to enhance anti-tumor effects through dual checkpoint inhibition and antibody-dependent cellular cytotoxicity (ADCC). The IMiD component acts as a molecular glue, binding to the cereblon (CRBN) E3 ubiquitin ligase complex to induce the degradation of transcription factors like Ikaros (IKZF1) and Aiolos (IKZF3), thereby stimulating T-cell and NK-cell activity. This combination is currently in Phase 1 clinical evaluation (NCT05009355) to assess safety and preliminary efficacy in patients with relapsed or refractory hematological malignancies.
- Other names
- OT-A201 + lenalidomideOT-A201 + pomalidomide
02
Targets
IKZF3 (Zinc finger protein Aiolos)SALL4 (Sal-like protein 4)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)
Beyond the preview
Go deeper on OT-A201 + IMiDs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OT-A201 + IMiDs.